Investor Presentaiton slide image

Investor Presentaiton

Core Operating Profit Decreased by 9.3 Bn JPY (Decreased by 9.1 Bn JPY excl. forex impact) FY2021 Q1 Results 43.7 Revenue Cost of Sales SG&A Expenses R&D Expenses Forex Impact FY2022 Q1 Results 34.4 17.4 16.2 14.4 Positive Factors 14.2 7.9 Negative Factors Revenue +16.2 incl. forex impact of +17.3 Cost of Sales -14.2 Daiichi-Sankyo (Bn JPY) Improvement in cost of sales ratio by change in product mix SG&A Expenses +7.9 Increase in expenses related to Enhertu due to an increase in profit share of gross profit with AstraZeneca R&D Expenses +14.4 Increase in 3ADCS* R&D investments Forex Impact +17.4 (Profit Decreased) Cost of Sales +3.7 SG&A Expenses +7.2 R&D Expenses +6.5 * 3ADCs: 1) Enhertu, Trastuzumab deruxtecan (T-DXd, DS-8201), 2) Datopotamab deruxtecan (Dato-DXd, DS-1062) and 3) Patritumab deruxtecan (HER3-DXd, U3-1402) 6
View entire presentation